Catalyst Pharmaceuticals (NASDAQ:CPRX) Cut to Equal Weight at Stephens

Stephens downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from an overweight rating to an equal weight rating in a research report report published on Thursday, MarketBeat reports.

A number of other analysts have also weighed in on CPRX. Zacks Research raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Friday, March 27th. Truist Financial raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Citigroup upped their target price on shares of Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a report on Friday, March 27th. Three investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.17.

Catalyst Pharmaceuticals Trading Down 0.1%

Catalyst Pharmaceuticals stock opened at $31.15 on Thursday. The firm’s 50 day simple moving average is $25.31 and its 200 day simple moving average is $23.93. The firm has a market capitalization of $3.81 billion, a PE ratio of 18.43, a price-to-earnings-growth ratio of 1.01 and a beta of 0.72. Catalyst Pharmaceuticals has a 1-year low of $19.05 and a 1-year high of $32.56.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Rothschild Investment LLC increased its holdings in shares of Catalyst Pharmaceuticals by 1,085.7% in the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 1,520 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 630 shares during the last quarter. Clearstead Advisors LLC increased its holdings in shares of Catalyst Pharmaceuticals by 192.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 1,167 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of Catalyst Pharmaceuticals by 552.7% in the 4th quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 1,564 shares during the last quarter. Finally, Advisory Services Network LLC bought a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter worth $39,000. Institutional investors own 79.22% of the company’s stock.

Key Stories Impacting Catalyst Pharmaceuticals

Here are the key news stories impacting Catalyst Pharmaceuticals this week:

• Positive Sentiment: Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for about $4.1 billion, or $31.50 per share in cash, which is above where the stock had been trading and typically supports a takeover premium. Closing is expected in the third quarter of 2026. Italy’s Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion
• Positive Sentiment: Catalyst also announced a settlement of its FIRDAPSE patent litigation with Hetero Labs, pushing any potential generic competition to January 2035 and resolving all pending FIRDAPSE patent disputes. That reduces legal overhang for the business. Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE Patent Litigation with Hetero Labs Ltd.
• Neutral Sentiment: The company canceled its first-quarter 2026 conference call and webcast, which may have drawn attention but does not appear to be a major fundamental development on its own. Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
• Negative Sentiment: Stephens downgraded Catalyst to Equal Weight from Overweight, which can weigh on sentiment even though the downgrade may be overshadowed by the acquisition bid. Stephens & Co. downgrades Catalyst Pharmaceuticals (CPRX)
• Negative Sentiment: Law firms announced shareholder investigations into whether Catalyst is receiving a fair price in the Angelini transaction, creating a small litigation-related overhang. Shareholder Alert: Ademi LLP investigates whether Catalyst Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).